1. Pi-Sunyer F.X. The epidemiology of central fat distribution in relation to disease // Nutrition Reviews. — 2004. — Vol. 62, № 7. — Р. 120–126.
2. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ // Mol. Cell. Endocrinol. — 2010. — Vol. 316, № 2. — Р. 129–139.
3. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity // Nat. Med. — 2001. — Vol. 7, № 8. — Р. 941–946.
4. Ohashi K., Ouchi N., Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin // Biochimie. — 2012. —Vol. 94, № 10. — Р. 2137–2142.
5. Han S., Quon M., Kim J. et al. Adiponectin and cardiovascular disease // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 5. — P. 531–538.
6. Беляева О.Д., Баженова Е.А., Березина А.В. и др. Уровень адипонектина, показатели липидного и углеводного обменов у пациентов с абдоминальным ожирением // Артериальная гипертензия. — 2009. — Т. 15, № 3. — С. 309–314. / Belyaeva O.D., Bazhenova E.A., Berezina A.V. et al. Adiponectin levels, lipid profile and glucose metabolism in patients with abdominal obesity // Arterial Hypertension. — 2009. — Vol. 15, № 3. — P. 309–314.
7. Matsubara M., Maruoka S., Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia // J. Clin. Endocrinol. Metab. — 2002. — Vol. 87, № 6. — P. 2764–2769.
8. Huang K., Chen C., Chuang L. et al. Plasma adiponectin levels and blood pressures in non-diabetic adolescent females // J. Clin. Endocrinol. Metab. — 2003. — Vol. 88, № 9. — P. 4130–4134.
9. Танянский Д.А., Парфенова Н.С. Адипонектин: благоприятное воздействие на метаболические и сердечно-сосудистые нарушения // Артериальная гипертензия. — 2013. — T. 19,
10. № 1. — С. 84–96. / Tanyanskiy D.A., Parfenova N.S. Adiponectin: the beneficial effects on metabolic processes and cardiovascular system // Arterial Hypertension. —2013. — Vol. 19, № 1. — P. 309–314.
11. Hara K., Horikoshi M., Yamauchi T. et al. Measurement of the high-molecular-weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome // Diabetes Care. — 2006. — Vol. 29, № 6. — Р. 1357–1362.
12. Heidemann C., Sun Q., van Dam R.M. et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women // Ann. Intern. Med. — 2008. — Vol. 149, № 5. — Р. 307–316.
13. Sattar N., Watt P., Cherry L. et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93, № 5. — Р. 1846–1849.
14. Pischon T., Hu F.B., Girman C.J. et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women // Atherosclerosis. — 2011. — Vol. 219, № 1. — Р. 322–329.
15. Aso Y., Yamamoto R., Wakabayashi S. et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin // Diabetes. — 2006. — Vol. 55, № 7. — Р. 1954–1960.
16. Kim D.H., Kim C., Ding E.L. et al. Adiponectin Levels and the risk of hypertension: a systematic review and meta-analysis // Hypertension. — 2013. — Vol. 62, № 1. — Р. 27–32.
17. Kawamoto R., Tabara Y., Kohara K. et al. Association of serum high molecular weight adiponectin and blood pressure among non-diabetic community-dwelling men // Clin. Experim. Hypertens. — 2011. — Vol. 33, № 5. — Р. 336–44.
18. Ogorodnikova A.D., Wassertheil-Smoller S., Mancuso P. et al. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study // Stroke. — 2010. — Vol. 41, № 7. — Р. 1376–1381.
19. Baumann M., von Eynatten M., Dan L. et al. Altered molecular weight forms of adiponectin in hypertension // J. Clin. Hypertens. — 2009. — Vol. 11, № 1. — Р. 11–16.
20. Alberti G. Introduction to the metabolic syndrome // Eur. Heart J. Suppl. — 2005. — Vol. 7, Suppl. D. — P. D3–D5.
21. Garrow J.S., Webster J. Quetelet's index (W/H2) as a measure of fatness // Int. J. Obes. — 1985. — Vol. 9, № 2. —Р. 147–153.
22. Matthews D., Hosker J., Rudenski D. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. — 1985. — Vol. 28, № 7. — P. 412–419.
23. The European cardiovascular disease risk assessment model. —. — URL: http://www.escardio.org (дата обращения — 10.10.2013).
24. Manson J.E., Skerrett P.J., Greenland P. et al. The escalating pandemic of obesity and sedentary lifestyle. A call to action for clinicians // Arch. Intern. Med. — 2004. — Vol. 164, № 3. — Р. 249–258.
25. Poirier P., Giles T.D., Bray G.A. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss : an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the Council on nutrition, physical activity, and metabolism // Circulation. — 2006. — Vol. 113, № 6. — Р. 898–919.
26. Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study // Lancet. — 2004. — Vol. 364, № 9438. — Р. 937–952.
27. Stamler J., Rose G., Stamler R. et al. INTERSALT study findings. Public health and medical care implications // Hypertension. — 1989. — Vol. 14, № 5. — Р. 570–577.
28. Garrison R.J., Kannel W.B., Stokes J.I. et al. Incidence and precursors of hypertension in young adults; the Framingham Offspring Study // Prevent. Med. — 1987. — Vol. 16, № 2. —Р. 235–251.
29. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease // Obes. Res. — 2003. — Vol. 11, № 11. — Р. 1278–1289.
30. Sinha R., Dufour S., Petersen K.F. et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relation-ships to insulin sensitivity, total body fat, and central adiposity // Diabetes. — 2002. — Vol. 51, № 4. — Р. 1022–1027.
31. Yusuf S., Hawken S., Ounpuu S. et al. INTERHEART Study Investigators: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study // Lancet. — 2005. — Vol. 366, № 9497. — Р. 1640–1649.
32. Katzmarzyk P.T., Craig C.L. Independent effects of waist circumference and physical activity on all-cause mortality in Canadian women // Appl. Physiol. Nutr. Metab. — 2006. — Vol. 31, № 3. — Р. 271–276.
33. Rocchini A.P. Obesity hypertension, salt sensitivity and insulin resistance // Nutr. Metab. Cardiovasc. Dis. — 2000. — Vol. 10, № 5. — Р. 287–294.
34. Hall J.E. The kidney, hypertension and obesity // Hypertension. — 2003. — Vol. 41, № 3. — Р. 625–633.
35. Асташкин Е.И., Глезер М.Г. Ожирение и артериальная гипертония // Проблемы женского здоровья. — 2008. — Т. 3, № 4. — С. 23–33. / Astashkin Ye.I., Glezer M.G. Obesity and arterial hypertension // Problems of Women Health. — 2008. — Vol. 3, № 4. — С. 23–33.
36. Ahima RS., Flier JS. Adipose tissue as an endocrine organ // Trends Endorinol. Metab. — 2000. — Vol. 11, № 8. —Р. 327-332.
37. Fruhbeck G., Gomez-Ambrosi J., Muruzabal F.J. et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation // Am. J. Physiol. Endocrinol. Metab. — 2001. — Vol. 280, № 6. — Р. E827–E847.
38. Чубенко Е. А. Уровень лептина, структурно-функциональные параметры сердца и сосудов у женщин с абдоминальным ожирением и артериальной гипертензией: автореферат дис. ... канд. мед. наук: 14.00.06; Санкт-Петербург. гос. мед. ун-т им. акад. И. П. Павлова. — СПб., 2009. — 16 с. / Chubenko E.A. Leptin level, structural and functional features of heart and vessels in women with abdominal obesity and hypertension: PhD thesis: 14.00.06; St Petersburg Pavlov State Medical University. — St Petersburg, 2009. — 16 p..
39. Weyer C., Funahashi T., Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia // J. Clin. Endocrinol. Metab. — 2001. — Vol. 86, № 5. — Р. 1930–1935.
40. Di Chiara T., Argano C., Corrao S., Scaglione R., Licata G. Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome // J. Nutr. Metab. — 2012. — Vol. 2012. — 175245. doi: 10.1155/2012/175245.
41. Pajvani U.B., Du X., Combs T.P. et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity // J. Biol. Chem. — 2003. — Vol. 278, № 11. — P. 9073–9085.
42. Kobayashi H., Ouchi N., Kihara S. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin // Circ. Res. — 2004. — Vol. 94, № 4. — Р. 27–31.
43. Okamoto Y., Kihara S., Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein K-deficient mice // Circulation. — 2002. — Vol. 106, № 22. — Р. 2767–2770.
44. Kubota N., Terauchi Y., Yamauchi T. et al. Disruption of adiponectin causes insulinresistance and neointimal formation // J. Biol. Chem. — 2002. — Vol. 277, № 29. — Р. 25863–25866.
45. Canale M.P., Manca di Villahermosa S., Martino G. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity // Int. J. Endocrinol. — 2013. — Vol. 2013.
46. Landsberg L. Hyperinsulinemia: possible role in obesity induced hypertension // Hypertension. — 1992. — Vol. 19, № 1. — Р. 161–166. — 865965. doi: 10.1155/2013/865965.